Home > PHARMA BUSINESS, PHARMACEUTICALCOMPANY > Novartis Signs Deal with Synthetic Genomics Vaccines

Novartis Signs Deal with Synthetic Genomics Vaccines

Novartis on Thursday announced that it has undergone a three-year deal to work in conglomeration with Synthetic Genomics Vaccines.
Novartis and San Diego-based Synthetic Genomic Vaccines aim to develop so-called seed viruses, templates using which large amounts of vaccine is produced based on Synthetic Genomics technology, Novartis posted in a statement today.

In addition, Novartis claims that with the new process, the time required for vaccine output would be lowered by over two months, which emerges as a potential case of a flu pandemic.
Today, Sucampo Pharmaceuticals and Abbott filed an application in Japan, seeking regulatory approval to reatil Amitiza, a drug for treating chronic idiopathic constipation.
The conglomerated work by the two giants is backed by the U. S. Biomedical Advanced R|esearch and Development  Authority, the government body that regulates vaccine and drug development for public-health emergencies.
As Novartis is focusing on a pandemic flu shot, the tie-up may also render its seasonal flu program at an advantage, claims the Siena-based Rappuoli.
Synthetic Genomics Vaccines was formed by a not-for-profit Venter institute and Synthetic Genomics Inc., a Company Venter created in 2005. Synthetic Genomics Inc. hails of its investors that include BP Plc and the venture-capital firm Draper Fisher Jurvetson.

  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: